T H E K O R E A N D O C T O R S W E E K L Y www.docdocdoc.co.kr I N S I D E 38 3 5 6 8 11 13 24 25 27 29 31 38 41 42
2 Advertisement
Government & Medicine 3 Government & Medicine
4 Government & Medicine
Government & Medicine 5
6 Government & Medicine
Advertisement 7
8 Government & Medicine
Advertisement 9
10 Government & Medicine
Government & Medicine 11
12 Advertisement
Government & Medicine 13
14 Government & Medicine
Government & Medicine 15
16 Cover Stories
Cover Stories 17 interview
18 Health & Science Health & Science
Advertisement 19
20 Health & Science
Advertisement 21
22 Advertisement
Health & Science 23 Research Trends Sharing Research Trends Sharing <Summary>
24 Specialties Specialties
Specialties 25
26 Advertisement
Specialties 27
28 Specialties
Specialties 29
30 Advertisement
Specialties 31
32 Business Business
Advertisement 33 Inhibiting receptors from the inside gives hope for life outside ErbB1 ErbB2 receptor Dual Tyrosine Kinase Inhibitor trastuzumab ErbB2+ TTP TTP: Time To Progression REFERENCES: 1. Spector NL et al, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol.2005 ; 23 : 2502-12. 2. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. NEJM 2006;355:2733-43. Prescribing Information
34 Advertisement
Business 35
36 2 0 1 1 0 1 1 0 Business
Advertisement 37
38 doctor s view Doctor s View
Advertisement 39
40 2 0 1 1 0 1 1 0 Advertisement
Doctor s View 41
42 제441회 글 주프로 그림 정훈이 Doctor s View
Advertisement 43 1. Data on file, Eli Lilly and Company 2. Ignaut D et al. J Diabetes Sci Technol 2008;2(3):533-537 Approval No.2009-237
THE KOREAN DOCTORS WEEKLY Monday, January 10, 2011